Nanoparticle crossing of blood-brain barrier: A road to new therapeutic approaches to central nervous system diseases
The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
the increase in lifespan in Western countries predicts that CNS diseases
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As such, the appropriate size range for DDS is between 100 and 200 nm.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [24]
In the citing paper
“however, to be able to cross the BBB, the literature indicates that NPs should be smaller than 200 nm [24].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [24]
Citations
Cites
Cost of disorders of the brain in Europe 2010
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., Faravelli, C., Fratiglioni, L., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.008 · Cited by 1,723
Current Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954
Lindgren, M., Hällbrink, M., Prochiantz, A., & Langel, Ü. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01447-4 · Cited by 803
Lin, T., Zhao, P., Jiang, Y., Tang, Y., Jin, H., Pan, Z., He, H., Yang, V. C., & Huang, Y. (2016) · ACS Nano · doi:10.1021/acsnano.6b04268 · Cited by 527
Wiley, D. T., Webster, P., Gale, A., & Davis, M. E. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307152110 · Cited by 519
Crossing the Blood–Brain Barrier: Recent Advances in Drug Delivery to the Brain
Patel, M. M., & Patel, B. M. (2017) · CNS Drugs · doi:10.1007/s40263-016-0405-9 · Cited by 430
Progress in brain targeting drug delivery system by nasal route
Khan, A. R., Liu, M., Khan, M. W., & Zhai, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.001 · Cited by 402
The burden of neurological disease in theUnitedStates: A summary report and call to action
Gooch, C. L., Pracht, E., & Borenstein, A. R. (2017) · Annals of Neurology · doi:10.1002/ana.24897 · Cited by 388
Designing super selectivity in multivalent nano-particle binding
Martinez-Veracoechea, F. J., & Frenkel, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105351108 · Cited by 346
Surface-Modified Nanocarriers for Nose-To-Brain Delivery: From Bioadhesion to Targeting
Sonvico, F., Clementino, A. R., Buttini, F., Colombo, G., Pescina, S., Stanisçuaski Guterres, S., Raffin Pohlmann, A., & Nicoli, S. (2018) · doi:10.20944/preprints201802.0077.v1 · Cited by 306
Cited by
Items 101–200 of 232
Nanoparticle-mediated therapeutic compounds delivery to glioblastoma
Gallego, L., & Ceña, V. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1810015 · Cited by 22
Self-citationRecent Advances in Nanomaterials for Neural Applications: Opportunities and Challenges
Sisubalan, N., Shalini, R., Ramya, S., Sivamaruthi, B. S., & Chaiyasut, C. (2023) · Nanomedicine · doi:10.2217/nnm-2023-0261 · Cited by 25
Kania, K., Wagner, W., & Pułaski, Ł. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031068 · Cited by 21
“While there exists a large body of published research on the mechanisms of nanoparticle transport through the BBB, BBB circumvention by nanoparticles for drug delivery purposes, and nanoparticle design for BBB crossing, there is a significant lack of mechanistic toxicological data on the actual impact of individual na…”
BackgroundLocalized Drug Delivery Systems in High‐Grade Glioma Therapy—From Construction to Application
Hauck, M., Hellmold, D., Kubelt, C., Synowitz, M., Adelung, R., Schütt, F., & Held‐Feindt, J. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200013 · Cited by 23
Multifunctional Superparamagnetic Stiff Nanoreservoirs for Blood Brain Barrier Applications
Osorio, Z. V., da Silva‐Candal, A., Piñeiro, Y., Iglesias‐Rey, R., Sobrino, T., Campos, F., Castillo, J., & Rivas, J. M. (2019) · Nanomaterials · doi:10.3390/nano9030449 · Cited by 21
Tentu, P. M., Bazaz, M. R., Pasam, T., Shaikh, A. S., Rahman, Z., Mourya, A., Kaki, V. R., Madan, J., & Dandekar, M. P. (2023) · International Journal of Neuroscience · doi:10.1080/00207454.2023.2286209 · Cited by 22
“Nanoformulation of drugs has been suggested as a preferred choice for the treatment of neurodegenerative disorders, as it facilitates the central nervous system (cNs) delivery of drugs [29–31].”
Zajdel, K., Janowska, J., Frontczak‐Baniewicz, M., Sypecka, J., & Sikora, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021122 · Cited by 21
Nanotechnological Advancements in the Brain Tumor Therapy: a Novel Approach
Angolkar, M., Paramshetti, S., Halagali, P., Jain, V. K., Patil, A. B., & Somanna, P. (2022) · Therapeutic Delivery · doi:10.4155/tde-2022-0035 · Cited by 22
Kumarasamy, M., & Sosnik, A. (2019) · Advanced Biosystems · doi:10.1002/adbi.201900123 · Cited by 19
Cyclodextrin-Based Nanoparticles for Delivery of Antisense Oligonucleotides Targeting Huntingtin
Mendonça, M. C. P., Sun, Y., Cronin, M. F., Lindsay, A. J., Cryan, J. F., & O’Driscoll, C. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020520 · Cited by 20
“The physicochemical properties of the three CDs evaluated were similar and with uniform distribution, showing desirable characteristics for brain delivery (<200 nm and positively charged) [31], strong stability, and protecting ASO from nuclease degradation.”
BackgroundNanotechnology-enabled therapies improve blood-brain barrier challenges in brain tumor
Wenqi, Y., Lingxi, W., Mehmood, A., & Shah, W. (2023) · International Journal of Polymeric Materials · doi:10.1080/00914037.2023.2291105 · Cited by 24
Nowak, I., Madej, M., Secemska, J., Sarna, R., & Strzałka‐Mrozik, B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071931 · Cited by 18
Silant’ev, V. E., Belousov, A. S., Trukhin, F. O., Struppul, N. E., Shmelev, M. E., Patlay, A. A., Shatilov, R. A., & Kumeiko, V. V. (2024) · Biomedicines · doi:10.3390/biomedicines12071393 · Cited by 19
Hamdaoui, Q., Zekri, Y., Richard, S., Aubert, D., Guyot, R., Markossian, S., Gauthier, K. C., Gaie-Levrel, F., Bencsik, A. A., & Flamant, F. (2021) · Chemosphere · doi:10.1016/j.chemosphere.2021.132253 · Cited by 21
Bonan, N. F., Ledezma, D. K., Tovar, M. A., Balakrishnan, P. B., & Fernandes, R. (2022) · Nanomaterials · doi:10.3390/nano12152645 · Cited by 19
“Nanoparticles that are too large (>200 nm) cannot effectively cross the blood–brain barrier [48,49] while nanoparticles with a positive surface charge can form nonspecific ionic adhesions to the negatively charged cell membranes and extracellular space of the CNS [50], resulting in unwanted off-target binding and/or t…”
BackgroundLi, H., Guan, M., Zhang, N.-N., Wang, Y., Liang, T., Wu, H., Wang, C., Sun, T., & Liu, S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117011 · Cited by 17
Phuna, Z. X., Panda, B. P., Shivashekaregowda, N. K. H., & Madhavan, P. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102921 · Cited by 19
Vinaud, M. C., Real, D. A., Fraga, C. M., de Lima, N. F., Lino, R. D. S., Leonardi, D., & Salomon, C. J. (2020) · Therapeutic Delivery · doi:10.4155/tde-2020-0017 · Cited by 15
Calero, M., Moleiro, L. H., Sayd, A., Dorca, Y., Miquel-Rio, L., Paz, V., Robledo‐Montaña, J., Enciso, E., Acción, F., Herráez‐Aguilar, D., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.887678 · Cited by 14
“In our nanotechnological approach, to the best association with genemodulated BAMs able to affect the neurovascular unit in the BBB, the GR@LNPs are engineered for highest GR payload compared to the previous CLO-based approaches.”
BackgroundInfluentialPatlay, A. A., Belousov, A. S., Silant’ev, V. E., Shatilov, R. A., Shmelev, M. E., Ковалев, В. В., Perminova, I. V., Baklanov, I., & Kumeiko, V. V. (2023) · Polymers · doi:10.3390/polym15153280 · Cited by 14
“Most of the particles will be taken up through caveolin-mediated endocytosis and the remaining part through clathrin-mediated endocytosis [51].”
BackgroundLu, C. T., Ouyang, J., & Zhang, J. (2024) · Discover Nano · doi:10.1186/s11671-024-04139-w · Cited by 16
“Such strong initial binding affinity between core–shell UCNPs and cells was reported to enhance the cellular uptake, followed by enhancing transport ability via exocytosis to cross the barriers [68, 69].”
Akbaba, H., Erel‐Akbaba, G., & Şentürk, Ş. (2021) · Nanomedicine · doi:10.2217/nnm-2020-0412 · Cited by 15
Posadas, I., Romero‐Castillo, L., Ronca, R.-A., Karpus, A. O., Mignani, S. M., Majoral, J., Muñoz‐Fernández, M. Á., & Ceña, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084391 · Cited by 17
“This lack of NP efficiency can be due to the difficulty NPs face in crossing the blood–brain barrier (BBB) that stands between the blood stream and the brain parenchyma, strongly limiting the passage of foreign substances, such as drugs and NPs, into the brain [6] and/or contributing to the difficulty for NPs to enter…”
BackgroundSelf-citationMurugan, R., Mukesh, G., Haridevamuthu, B., Priya, P. S., Pachaiappan, R., Almutairi, B. O., Arokiyaraj, S., Guru, A., & Arockiaraj, J. (2023) · Biomass Conversion and Biorefinery · doi:10.1007/s13399-023-04343-1 · Cited by 13
“These engineered cus-tomisable devices with sizes in the order of nanometres have recently been suggested as an attractive tool, perhaps capable of solving the unmet problem of increasing medication transport across the BBB [12].”
Singh, M., Agarwal, V., Jindal, D., Pancham, P., Agarwal, S., Mani, S., Tiwari, R. K., Das, K., Alghamdi, B. S. A., Abujamel, T. S., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13030337 · Cited by 18
The Role of Iron Metabolism in Sepsis-associated Encephalopathy: a Potential Target
Liu, Y., Hu, S., Shi, B., Yu, B., Luo, W., Peng, S., & Du, X. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03870-2 · Cited by 15
“At the same time, the BBB will also affect the diffusion of drugs to brain tissue to a certain extent [147].”
Advances in the study of polydopamine nanotechnology in central nervous system disorders
Ren, S., Xiao, X., Lv, J., Lv, S., Wang, X. T., Liu, R., & Kong, Q.-X. (2024) · Frontiers in Materials · doi:10.3389/fmats.2024.1396397 · Cited by 12
Role of Polymeric Local Drug Delivery in Multimodal Treatment of Malignant Glioma: A Review
Tseng, Y., Chen, T., & Liu, S. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s309937 · Cited by 15
Ali, M. M., Shoukri, R. A., & Yousry, C. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105693 · Cited by 18
Panda, P., Mohanty, S., Gouda, S. R., Baral, T. C., Mohanty, A., Nayak, J., & Mohapatra, R. (2025) · Nutritional Neuroscience · doi:10.1080/1028415x.2025.2472773 · Cited by 12
“Such polymer coatings, especially with polyethylene glycol (PEG), will probably reinvent this process by creating barriers around the nanocar-riers that would prevent opsonization and clearance by the mononuclear phagocyte system, in itself [107].”
Gawas, C. G., Mathur, S., Wani, M., & Tabassum, H. (2023) · Ibrain · doi:10.1002/ibra.12091 · Cited by 12
“They aid in the removal of harmful substances from the brain, which is important for reducing the toxic side effects of CNS drug metabolites, and they restrict the entry of molecules into the brain by promoting luminal release of compounds.(19,20) 4 | ROLE OF N.”
BackgroundThink Big, Start Small: How Nanomedicine Could Alleviate the Burden of Rare CNS Diseases
Faouzi, A., & Roullin, G. (2021) · Pharmaceuticals · doi:10.3390/ph14020109 · Cited by 14
Impact of Protein Corona Formation on the Thermoresponsive Behavior of Acrylamide-Based Nanogels
Traldi, F., & Resmini, M. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.3c01405 · Cited by 11
Martins, F., Arada, R., Barros, H. L., Matos, P., Ramalho, J. S., Ceña, V., Bonifácio, V. D. B., Gonçalves, L. G., & Serpa, J. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00906-8 · Cited by 12
“Therefore, many chemotherapeutic drugs and targeted therapies are unable to effectively penetrate the BBB, limiting their ef fi cacy in treating GBM. Strategies to bypass or disrupt the BBB are being explored, such as nanotechnology [7, 8], to improve drug delivery to the brain tumor.”
Self-citationBattaglini, M., Feiner‐Gracia, N., Tapeinos, C., Pasquale, D. D., Pucci, C., Marino, A., Bartolucci, M., Petretto, A., Albertazzi, L., & Ciofani, G. (2022) · Nanoscale · doi:10.1039/d2nr00484d · Cited by 10
Mondal, I., Fatima, S. W., Priya, S., Sengupta, S., Khare, S. K., & Kulshreshtha, R. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c00189 · Cited by 10
Lab-On-A-Chip for the Development of Pro-/Anti-Angiogenic Nanomedicines to Treat Brain Diseases
Parimalam, S. S., Bǎdilescu, S., Sonenberg, N., Bhat, R., & Packirisamy, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246126 · Cited by 15
“One of the potential alternatives to overcome this challenge is to engineer NMs that take advantage of the properties of BBB and their transcellular routes [78].”
BackgroundVaginal Nanoformulations for the Management of Preterm Birth
Mir, A., Patel, K. R., Vartak, R., Yellon, S. M., & Reznik, S. E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102019 · Cited by 11
“Impaired drug delivery can result in poor efficacy, low bioavailability, and toxic effects [55,56].”
BackgroundKaur, J., Jakhmola, S., Singh, R. R., Joshi, B., Jha, H. C., & Joshi, A. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00430 · Cited by 10
Rabanel, J., Delbreil, P., Banquy, X., Brambilla, D., & Ramassamy, C. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.035 · Cited by 10
Neural Regenerative Nanomedicine
(2020) · Elsevier eBooks · doi:10.1016/c2019-0-01415-x · Cited by 10
Neuronal maturation-dependent nano–neuro interaction and modulation
Gupta, P., Rathi, P., Gupta, R., Baldi, H., Coquerel, Q., Debnath, A., Derami, H. G., Raman, B., & Singamaneni, S. (2023) · Nanoscale Horizons · doi:10.1039/d3nh00258f · Cited by 9
Saleh, S. R., Khamiss, S. E., Madhy, S. A., Khattab, S. N., Sheta, E., Elnozahy, F. Y., Thabet, E. H., Ghareeb, D. A., Awad, D., & El-Bessoumy, A. A. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125021 · Cited by 8
Korshoj, L. E., Shi, W., Duan, B., & Kielian, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670931 · Cited by 8
Figueroa, E. G., Caballero-Román, A., Grau, J. R. T., Carmona, M. M., Nardi-Ricart, A., & González‐Candia, A. (2022) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2022.100129 · Cited by 11
Progresses in the establishment, evaluation, and application of in vitro blood–brain barrier models
Yin, P., & Wang, X. (2024) · Journal of Neuroscience Research · doi:10.1002/jnr.25359 · Cited by 8
“The nanomaterials may take advantages of adsorptive-and receptor-mediated transcytosis to facilitate the binding of nanoparticles to the luminal plasma membrane of endothelial cells and then deliver drugs to the brain tissues (Ceña & Játiva, 2018).”
BackgroundRusso, A., Maiorano, G., Cortese, B., D’Amone, S., Invidia, A., Quattrini, A., Romano, A., Gigli, G., & Palamà, I. E. (2024) · Nanoscale · doi:10.1039/d4nr03159h · Cited by 8
Targeting Alzheimer's pathophysiology with carbon dots: from mechanisms to therapy
Tripathi, S., Singh, R., Jaiswal, S., Sethi, M., Rana, R., Mishra, K., & Chourasia, M. K. (2026) · Journal of Materials Chemistry B · doi:10.1039/d5tb02134k · Cited by 8
Goswami, S., Исаев, Н. К., Salmin, V. V., Rana, S. V. S., Illarioshkin, S. N., & Verma, Y. (2024) · Brain Disorders · doi:10.1016/j.dscb.2024.100162 · Cited by 8
Vesicle-based formulations for pain treatment: a narrative review
Martínez, J. C., Ingram, N., Kapur, N., Jayne, D. G., & Beales, P. A. (2024) · PAIN Reports · doi:10.1097/pr9.0000000000001196 · Cited by 8
Lavezzi, A. M., Pusiol, T., & Paradiso, B. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19074164 · Cited by 7
Nanodelivery of antiretroviral drugs to nervous tissues
Lawal, S. K., Olojede, S. O., Faborode, O. S., Aladeyelu, O. S., Matshipi, M. N., Sulaiman, S. O., Naidu, E. C., Rennie, C. O., & Azu, O. O. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1025160 · Cited by 8
“The ability of nanoparticles to cross the BBB has been identified as a therapeutic approach to reducing CNS diseases (Cena and Jativa, 2018).”
BackgroundAdverse Effects of Non-Metallic Nanoparticles in the Central Nervous System
Sikorska, K., Sawicki, K., Czajka, M., Kapka‐Skrzypczak, L., Kruszewski, M. K., & Brzóska, K. (2023) · Materials · doi:10.3390/ma16237264 · Cited by 7
Modified biopolymer-based systems for drug delivery to the brain
Thakur, A., Sidu, R. K., Gaurav, I., Kumari, S., Chakraborty, P., & Thakur, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821437-4.00016-5 · Cited by 8
Hassan, D., Sani, A., & Medina, D. I. (2023) · Springer eBooks · doi:10.1007/978-981-99-6940-1_8 · Cited by 9
Youssef, B., Ibrahim, E. A., Moselhy, S. S., ElShebiney, S. A., & ELabd, W. K. (2025) · Discover Nano · doi:10.1186/s11671-025-04356-x · Cited by 11
“It has been shown, nonetheless, that as BBB permeability varies from rodents to human beings, selecting the appropriate in vivo disease model is vital to assessing the capacity of the NPs to traverse the BBB [20].”
InfluentialPan, W., Shie, M., Yan, W.-Y., Chang, Y., Iao, H. M., Liu, H., Tran, N., Lee, I., Lien, H., Hsu, R., et al. (2026) · Advanced Composites and Hybrid Materials · doi:10.1007/s42114-026-01617-w · Cited by 10
“This reduced lysosomal retention is consistent with prior reports that conductive or magnetoelectric nanostructures generate localized electric fields upon exposure to alternating magnetic fields, inducing transient vesicular and membrane destabilization that facili - tates cytosolic release [69 ].”
Khafaga, D. S. R., Muteeb, G., Aswa, D. W., Aatif, M., Farhan, M., & Allam, S. (2025) · SLAS DISCOVERY · doi:10.1016/j.slasd.2025.100213 · Cited by 6
New Perspective in Alzheimer’s Disease: Theranostic Strategy
Cantore, M. (2019) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2019.15.002648 · Cited by 8
Surendra, D. M., Chamaraja, N. A., Godipurge, S. S., & Yallappa, S. (2022) · Results in Chemistry · doi:10.1016/j.rechem.2022.100565 · Cited by 6
Phytoconstituents-based nanoformulations for neurodegenerative disorders
Rajput, M. S., Nirmal, N. P., Patel, V. A., Sarkar, P. D., & Raval, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-19143-5.00003-7 · Cited by 9
Nanoparticles for the potential treatment of Alzheimer’s disease: A physiopathological approach
Martínez, N. M. N., Toledo, J. A., & Morales, J. O. (2023) · Nanotechnology Reviews · doi:10.1515/ntrev-2022-0548 · Cited by 9
Rani, V., Venkatesan, J., & Prabhu, A. (2024) · Journal of Cluster Science · doi:10.1007/s10876-023-02511-x · Cited by 6
Hollow Multicomponent Capsules for Biomedical Applications: A Comprehensive Review
Anis, T., Hassan, S. M. U., Khurshid, A., Fakhar-e-alam, M., Shahzad, F., Ali, A., Ahmad, J., & Hossain, N. (2022) · Journal of Cluster Science · doi:10.1007/s10876-022-02272-z · Cited by 8
Does Nanosilver Have a Pronounced Toxic Effect on Humans?
Ivlieva, A. L., Николаевна, П. Е., Рогаткин, Д. А., Yushin, N. S., Grozdov, D., Vergel, K., & Zinicovscaia, I. I. (2022) · Applied Sciences · doi:10.3390/app12073476 · Cited by 6
Rajput, S., Malviya, R., Sridhar, S. B., Wadhwa, T., Shareef, J., & Rana, A. (2025) · Nano-Structures & Nano-Objects · doi:10.1016/j.nanoso.2025.101516 · Cited by 4
Amadu, M., Raheem, N. M., & Miadonye, A. (2025) · Nanomaterials · doi:10.3390/nano15171330 · Cited by 3
Roamcharern, N., & Yubolphan, R. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1810486 · Cited by 5
“…efficiency has progressed, nanoparticles with smaller diameters ( < 200 nm) have emerged as a promising size range for enhancing BBB penetration, whereas those with diameters > 200 nm exhibit reduced permeability across the BBB (Betzer et al., 2017; Ceña and Játiva, 2018; Hersh et al., 2022).”
Meyer, Z. A., & Rambharose, S. (2025) · BioMetals · doi:10.1007/s10534-025-00757-8 · Cited by 4
“Surface modification, such as capping the surface, or conjugation with specific antibodies and surfactants, further enhances NP’s ability to overcome treatment challenges such as the BBB permeability (Zhang et al. 2016; Ceña and Játiva 2018).”
Gatti, A. M., Ristić, M., Stanzani, S., & Lavezzi, A. M. (2022) · Nanomedicine · doi:10.2217/nnm-2021-0203 · Cited by 4
Nano-curcumin in Neurodegenerative Diseases
Napagoda, M. T. (2023) · Springer eBooks · doi:10.1007/978-981-99-7731-4_15 · Cited by 4
Alonso, M., Barcia, E., Negro, S., Paccione, N., Rahmani, M., Montejo, C., García‐García, L., & Fernández-Carballido, A. M. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106680 · Cited by 5
Drug Encapsulation and Nanocarriers for Targeted Delivery in Animals
Jain, U., & Chauhan, N. (2019) · Springer eBooks · doi:10.1007/978-3-319-97852-9_18 · Cited by 5
Mishra, N. T. P., Yadav, S. S., Khantwal, M., Khan, W., & Khan, S. A. (2022) · Indo Global Journal of Pharmaceutical Sciences · doi:10.35652/igjps.2022.12005 · Cited by 4
Jain, H., Dhawan, P., Rao, S., Lalwani, N., & Shand, H. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220901101204 · Cited by 4
Kubelt, C., Hellmold, D., Peschke, E., Hauck, M., Will, O., Schütt, F., Lucius, R., Adelung, R., Scherließ, R., Hövener, J., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11061518 · Cited by 6
Lin, Y. (2024) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-031-49744-5_6 · Cited by 6
Transporter Systems and Metabolism at the Blood–Brain Barrier and Blood–CSF Barrier
Verma, K., Kapoor, D. U., Jain, S., Singh, R., & Sharma, S. K. (2023) · Springer eBooks · doi:10.1007/978-981-99-6807-7_3 · Cited by 6
Khotimah, H., Rahmaniar, F. Z., Zahra, F. A., Anaqah, R., Kurniawan, S. N., Rahayu, M., & Sulistomo, H. W. (2024) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2024.26.3.0099 · Cited by 4
Biomaterials and Stem Cells as Drug/Gene-Delivery Vehicles for Parkinson’s Treatment: An Update
Roshani, M., Kiaie, N., & Aghdam, R. M. (2021) · Regenerative Medicine · doi:10.2217/rme-2021-0050 · Cited by 4
Sahu, S., Telegaonkar, S., & Mishra, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13474-6.00002-0 · Cited by 3
Ortega-Fimbres, O., Montiel‐Herrera, M., García‐Villa, D., Delgado, F. J. P., Monge-Sanchez, D., Fernández‐Quiroz, D., de la Re-Vega, E., Molina-Domínguez, C. C., Ángulo-Molina, A., del Campo, C. C.-M., et al. (2023) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2023.2224878 · Cited by 3
Herrera, G., Scimonelli, T. N., Lasaga, M., Granero, G. E., & Onnainty, R. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109969 · Cited by 3
Emerging Nanomaterials in Drug Delivery and Therapy
Nargis, M. (2023) · Materials research foundations · doi:10.21741/9781644902172-6 · Cited by 2
Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?
Timon-David, É., Perez, C., & Rodallec, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112326 · Cited by 4
“, lipophilicity, permeability, and distribution) [69,70,72].”
The role of blood–brain and blood–retinal barriers in drug delivery
Bonilla-Vidal, L., Esteruelas, G., Souto, E. B., Espina, M., García, M. L., & López, E. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90471-1.00002-5 · Cited by 4
Silva, R., Monteiro, J., Ramalho, M. J., Andrade, S., Loureiro, J. A., & Pereira, M. C. (2026) · Pharmaceuticals · doi:10.3390/ph19050685 · Cited by 2
“Studies assure the safety of NPs with diameters above 100 nm [23]; however, to be able to cross the BBB, the literature indicates that NPs should be smaller than 200 nm [24].”
Material considerations for delivering therapeutics across the blood–brain barrier
Zoba, A. N., & Tringides, C. M. (2025) · APL Materials · doi:10.1063/5.0284305 · Cited by 2
Ciont, C., Mesaroş, A., Pop, R., Barbu–Tudoran, L., Bortnic, R. A., Rugină, D. O., Tăbăran, A.-F., Diaconeasa, Z. M., Suharoschi, R., Pop, O. L., et al. (2025) · BioNanoScience · doi:10.1007/s12668-025-02217-6 · Cited by 2
“In nanomedicine, particle size is an essential aspect [45].”
The olfactory epithelium as a gateway for bloodborne nanoparticles to the central nervous system
Sharapova, M. B., Amelina, K. A., Kazakova, L. I., Ilchibaeva, T. V., Zuev, D. S., Solovieva, O. I., Morozova, K. N., Zhukova, M. V., Владимировна, К. Е., Sukhorukov, G. B., et al. (2025) · Biomaterials Science · doi:10.1039/d5bm01311a · Cited by 3
Bahrami, F., Rahimzadeh, S., Boojar, M. M. A., Baqeri, A., Ghorbani, M., & Saberi, M. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.08.004 · Cited by 2
“Several nanobiotherapy approaches have been adopted in the field of nanoparticle-based drug delivery systems to overcome the Bood-Brain Barrier (BBB) (Teleanu et al., 2018; Hersh et al., 2022; Ahlawat et al., 2020; Ce ˜ na and J ´ ativa, 2018).”
Nanomaterial-based drug delivery systems as tools for targeted therapy of neurodegenerative diseases
Shukla, R., Srivastava, V., Sethi, A., & Ruwali, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85544-0.00003-4 · Cited by 3
A Comprehensive Review on Inorganic Nanoparticles as Effective Modulators of Amyloidogenesis
Chakraborty, D., Mukherjee, A., & Sarkar, N. (2023) · Protein and Peptide Letters · doi:10.2174/0929866530666230705153229 · Cited by 2
Belko, S., Babayemi, O. H., Baker, C., Fowler, M., Masouleh, M. P., Householder, K. T., Stabenfeldt, S. E., & Sirianni, R. W. (2021) · Research Square · doi:10.21203/rs.3.rs-704464/v1 · Cited by 2
Challenges and Emerging Problems in Nanomedicine Mediated Gene Therapy
Bhatt, S., Faridi, N., Pathak, R., Punetha, V. D., & Punetha, M. (2023) · Wiley eBooks · doi:10.1002/9781394175635.ch13 · Cited by 3
Unveiling new horizons: Investigating Ayurveda’s role in managing neurological disorders
Acharya, R. (2024) · Journal of Research in Ayurvedic Sciences · doi:10.4103/jras.jras_108_24 · Cited by 1
In Vitro and In Vivo Techniques to Assess Neurotoxicity of Nanoparticles
Birngruber, T., Okereke, J., Shapovalov, V. S., Fröhlich, E., Sinner, F. M., Yu, J. S., Hsieh, M., Kateb, B., & Pieber, T. R. (2024) · Springer eBooks · doi:10.1007/978-3-030-80662-0_33 · Cited by 1
Bioinspired green synthesis of nanoparticles by plants to fight against multidrug resistant microbes
SHENDE, S. S., Ingle, P. U., Sonawane, A., Jungari, P., Rajput, V. D., Minkina, T., Prokisch, J., Golińska, P., Rai, M. K., & Gade, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29044-2.00019-9 · Cited by 1
Muolokwu, C. E., Gothwal, A., Kanekiyo, T., & Singh, J. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03900-9 · Cited by 1
“The particle size of liposomes significantly influences their ability to cross the BBB. Research studies have shown that nano-particles larger than 200 nm are quickly eliminated from the bloodstream by the lymphatic system and struggle to cross the BBB in vivo [54].”
Optimization of cationic functionalized nanoparticles for brain targeting: in vivo evaluation
Pereira, K. A. B., Premazzi, M. C. A., Gonçalves, V. D. L., da Silva, B. J. D., Várady, C. B. S., de Souza, M. A. C., Müller, R., Bastos, R., Mansur, C. R. E., & Jurgilas, P. B. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152797 · Cited by 2
Metadata
- Authors
- Ceña, V., & Játiva, P.
- Affiliations
- Unidad Asociada Neurodeath, Universidad de Castilla-La Mancha, Albacete, Spain
- Instituto de Salud Carlos III (ES)
- ORCID
- Játiva, Pablo
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2018-07
- Volume
- 13
- Issue
- 13
- Pages
- 1513-1516
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W2868168748
- Semantic Scholar
- f5267cc2f2cb4aee9679939ee9c77f593ddb94ac
- Cited by
- 232
- References
- 21
- Citations by year
- 2026: 14 · 2025: 27 · 2024: 31 · 2023: 47 · 2022: 45 · 2021: 32 · 2020: 21 · 2019: 14 · 2018: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nanomedicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Keywords
- blood-brain barrier, nanoparticles, nanoparticle delivery, central nervous system disorders, brain drug delivery, neurodegenerative diseases, neuroinflammation
- MeSH terms
- Biological Transport, Blood-Brain Barrier, Central Nervous System, Central Nervous System Diseases, Humans, Drug Delivery Systems, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.